References
- Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29 https://doi.org/10.3322/canjclin.48.1.6
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29 https://doi.org/10.3322/canjclin.54.1.8
- Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest 1997;112:251S-8S https://doi.org/10.1378/chest.112.1.251
- Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001;31:123-37 https://doi.org/10.1016/S0169-5002(00)00197-5
- Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002;346:85-91 https://doi.org/10.1056/NEJMoa003034
- Chua YJ, Steer C, Yip D. Recent advances in management of small cell lung cancer. Cancer Treat Rev 2004;30:521-43 https://doi.org/10.1016/j.ctrv.2004.06.003
- Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer. J Clin Oncol 2004;22:4837-45 https://doi.org/10.1200/JCO.2004.01.178
- Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992;327:1618-24 https://doi.org/10.1056/NEJM199212033272302
- Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:800-5
- Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60 https://doi.org/10.1200/JCO.2002.12.071
- Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-44 https://doi.org/10.1200/JCO.1993.11.2.336
- Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 1997;15:3030-7 https://doi.org/10.1200/JCO.1997.15.9.3030
- Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer: a randomized study. J Clin Oncol 1997;15:893-900 https://doi.org/10.1200/JCO.1997.15.3.893
- World Health Organization. WHO handbook for reporting results of cancer treatment: WHO offset publication No. 48. Geneva, Switzerland: World Health Organization; 1979
- Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CfCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13: 176-81 https://doi.org/10.1016/S1053-4296(03)00031-6
- Zheng T, Nathanson MH, Elias JA. Histamine augments cytokine-stimulated IL-11 production by human lung fibroblasts. J ImmunoI 1994;153:4742-52
- Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 2005;11:5534-8 https://doi.org/10.1158/1078-0432.CCR-04-1771
- Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993;68:777-82 https://doi.org/10.1038/bjc.1993.427
- Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K, et al. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small cell lung cancer (JOOG9902-DI). Ann Oncol 2003;14:709-14 https://doi.org/10.1093/annonc/mdg213
- Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, et al. [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group]. Gan To Kagaku Ryoho 1991;18:1013-9
- Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1900;50: 5919-24
- Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Anoka H, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 1996;56:789-93
- Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. J Clin Oncol 2006; 24:2038-43 https://doi.org/10.1200/JCO.2005.04.8595
- Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive stage small cell lung cancer. J Clin Oncol 1994; 12:2022-34 https://doi.org/10.1200/JCO.1994.12.10.2022
- Green MR, Cox JD, Ardizzoni A, Arriagada R, Bureau G, Darwish S, et al. Endpoints for multimodal clinical trials in Stage III non-small cell lung cancer (NSCLC): a consensus report. Lung Cancer 1994;11 Suppl 3:S11-3 https://doi.org/10.1016/0169-5002(94)91859-7
- De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small cell lung cancer. Ann Oncol 2006;17:543 - 52 https://doi.org/10.1093/annonc/mdj094
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-74 https://doi.org/10.1200/JCO.1990.8.9.1563
- Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM Asthma. From bronchoconstrietion to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-45 https://doi.org/10.1164/ajrccm.161.5.9903102
- Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71 https://doi.org/10.1056/NEJM199901283400403
- Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small cell lung carcinoma. J Clin Oncol 1999;17:2681-91 https://doi.org/10.1200/JCO.1999.17.9.2681